Introduction
▼ An estimated 3.2 million new cases of cancer and 1.7 million deaths from cancer occurred in Europe in 2008 [ 1 ] . The fact that only 5-10 % of all cancer cases are due to genetic defects and that the remaining 90-95 % are due to lifestyle factors (including smoking, alcohol, physical inactivity, obesity and sun exposure), nutrition, infections and environmental pollutants provide major opportunities for preventing cancer [ 1 ] . Malignant melanoma is a tumor derived from melanocytes, manifesting mainly on the skin, and in rare cases, from mucous membranes. The tumor-specifi c 10-year survival for patients with primary melanomas without any evidence of metastasis is 75-85 %, decreasing to 20-40 % for those patients with clinically apparent regional lymph node metastases. Distant organ metastases (stage IV disease) have a poor prognosis with a median survival in untreated patients of 6-9 months [ 2 ] .
It has been reported that cancer patients frequently express low ascorbate (ascorbic acid, vitamin C) blood levels. However, so far this was not shown for melanoma patients. Total ascorbate (TAA) levels were determined in plasma of healthy control individuals (n = 31, mean age: 47.3 years, TAA: 64.86 μM) and in 126 melanoma patients (stage I: n = 30, mean age: 51 years, TAA: 59.95 μM; stage II: n = 30, mean age: 46.8 years, TAA: 58.85 μM; stage III: n = 32, mean age: 48.6 years, TAA: 57.27 μM; stage IV: n = 34, mean age: 51.1 years, TAA: 47.16 μM). Plasma TAA levels in stage IV patients were signifi cantly reduced by 27.3 % when compared to healthy individuals (p = 0.0001, t-test). The reduced plasma TAA levels in stage IV patients negatively correlated with increased S100 and lactate dehydrogenase (LDH) levels. Further, plasma TAA levels were determined in additional 9 stage IV patients directly before and 24 h after intravenous polychemotherapy (carboplatin + paclitaxel, n = 5) or immunotherapy (ipilimumab, n = 4). TAA levels signifi cantly decreased 24 h after therapy (mean TAA before therapy: 48.7 μM; mean TAA after therapy: 43.0 μM; 11.4 % reduction, p < 0.05, t-test). Ascorbate levels in the plasma of 126 melanoma patients were signifi cantly decreased in the cohort of stage IV patients and were further decreased by polychemo-or immunotherapy in stage IV patients. Considering the importance of adequate ascorbate supply, ascorbate substitution in physiological doses could be considered for late-stage melanoma patients. enhances interferon production [ 7 ] . In line, impairment of lymphocyte activation, and macrophage and neutrophil mobilization were reported in scorbutic animals [ 9 ] .
Aim of the study : Considering the importance of adequate ascorbate supply for hundreds of biochemical processes and a functional immune system, we asked whether plasma ascorbate levels correlated with disease stage in patients affl icted with malignant melanoma and whether intravenous systemic therapy (polychemotherapy or immunotherapy) in stage IV melanoma patients infl uenced the plasma ascorbate level.
Materials and Methods

▼
Ethics statement
The use of human plasma samples was approved by the medical ethical committee of the University of Tuebingen, Germany, and was performed in accordance with the Declaration of Helsinki Principles. The plasma samples were gathered during routine blood withdrawals. Every patient signed an informed consent form prior to blood withdrawal allowing the determination of plasma ascorbate level for research purposes.
Recruitment of patients and controls
Patients aged 18 years and older included in this study. Patients with artifi cial ascorbate supplementation (e. g. taking ascorbateor multi-vitamin pills) were excluded from this study. The control cohort consisted of healthy volunteering employees (nurses, dermatologists and laboratory staff ) of the Department of Dermatology, University of Tuebingen, Germany, aged 18 years and older and was stratifi ed by the exclusion criteria stated above. The control cohort and the stage I and stage II melanoma patients had an ECOG Performance Status grade 0. The stage III melanoma patients had an ECOG Performance Status grade 0 or 1, and the stage IV melanoma patients grade 3 or 4.
HPLC ascorbate measurements
For the quantifi cation of ascorbate in EDTA-plasma, samples were immediately mixed with an equal amount of 5 % perchloric acid (Sigma, Munich, Germany) and stored at −80 °C. The time between blood withdrawal and snap-freezing was less than 10 min. For analysis of plasma ascorbate content, samples were thawed and centrifuged at 13 000 × g for 5 min at 4 °C. For reduction of DHA and determination of TAA, the supernatant was mixed with 0.15 M aqueous Tris(2-carboxyethyl)phosphine (TCEP, ABCR, Karlsruhe, Germany) solution (v/v: 2/1) and incubated for 5 min. Afterwards, the mixture was centrifuged at 13 000 × g for 5 min at 4 °C and transferred into light-protected micro-vials for chromatographic analysis. As external standards, 2 aqueous ascorbic acid solutions (50 μM and 100 μM) were prepared, diluted with an equal amount of perchloric acid (5 %), mixed with 0.15 M aqueous TCEP solution (v/v: 2/1) incubated for 5 min. The mixture was centrifuged at 13 000 × g for 5 min at 4 °C and transferred into light-protected micro-vials for chromatographic analysis. All analytical procedures were performed on ice and under dimmed light to avoid ascorbic acid degradation. For HPLC analysis, samples were placed in a cooled autosampler (Varian, Darmstadt, Germany). Chromatography was carried out on a reversed-phase column (Reprosil-Pur 120 C18 AQ 5 μM; Trentec, Gerlingen, Germany) with a mobile phase consisting of 5 mM aqueous sodium phosphate buff er, pH 2.5 at a fl ow rate of 1 ml/min. Detection was performed by using an electrochemical detector (ESA Detektor Coulochem II, Chelmsford, United Kingdom) and a Model 5011 high-sensitivity analytical cell (ESA) at −300 mV (E1, upstream) and + 300 mV (E2, downstream). Chromatograms were recorded and analyzed using Star chromatography workstation software version 5.31 (Varian, Darmstadt, Germany).
Statistical analysis
Statistical analysis of plasma ascorbate level was performed by using Student's t-test. P-values < 0.05 were considered as statistically signifi cant.
Results
▼
Plasma ascorbate is decreased in more advanced stages of melanoma and negatively correlates with plasma S100 and LDH levels Table 1 ). Plasma TAA levels constantly decreased from stage I to stage III, but the diff erence was not signifi cant when compared to the healthy controls. However, in stage IV patients the ascorbate plasma levels were signifi cantly reduced by 27.3 % when compared to healthy individuals (p = 0.0001, t-test). The ascorbate plasma levels of stage IV patients were also signifi - 
Plasma ascorbate decreases after poly-chemotherapy and immunotherapy
Second, we asked whether plasma ascorbate levels were infl uenced by systemic intravenous therapies performed on stage IV melanoma patients. To this end, plasma ascorbate levels were determined in 9 patients directly before and 24 h after either polychemotherapy (carboplatin + paclitaxel) or immunotherapy targeting CTLA4 (ipilimumab) [ 9 , 10 ] ( • ▶ Table 2 ). We could not fi nd a signifi cant diff erence of the reduction of plasma ascorbate levels caused by poly-chemotherapy when compared to immunotherapy.
Discussion
▼
Critical steps in the determination of plasma ascorbate levels
In this study we show for the fi rst time (to the best of our knowledge) that plasma ascorbate levels are reduced in stage IV melanoma patients when compared to healthy age-matched controls. Comparing the mean plasma ascorbate level of our healthy control cohort (64.86 μM), we fi nd a discrepancy in comparison to plasma ascorbate concentrations in the literature. In the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk prospective study), the mean ascorbate serum concentrations in the diff erent cohorts were 20.8-72.6 μM with a calculated mean of 47.3 μM (the exact mean was not communicated in the study) [ 11 ] . Secondly, in the more recent European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST), the mean ascorbate serum concentration in controls was 41.5 μM [ 12 ] . However, in the latter 2 studies the processing of the blood samples for the determina-tion of ascorbate levels was not comparable to the conditions used in the present study. According to the methods section of the 2 studies, the authors did not enforce a quick handling and freezing of the blood samples. Considering the importance of a quick processing (stabilization and subsequent freezing in liquid nitrogen), which is indispensable due to the instability of ascorbic acid, and which we performed within the short time of less than 10 min after blood withdrawal for all samples, this obvious diff erence in sample handling most likely accounts for the diff erence of ascorbate concentrations on our control group when compared to the mean values of the latter 2 studies. In line with this assumption, in the second National Health and Nutrition Examination Survey, the median serum ascorbate concentrations were 49.4 μM for men and 64.2 μM for women [ 13 ] . In the latter study, the mean ascorbate concentration was comparable to our control group, and the blood samples were put on dry ice after stabilization in the mobile examination centers without further storage at 7 °C over night. Thus, the quick stabilization and constant freezing (on dry ice) is comparable to the handling of the samples in our study and most likely accounts for the similar results obtained in the control samples. The lack of significant reduction of ascorbate plasma levels in stage I-III patients was obviously related to tumor burden. Stage I and II melanoma patients are completely tumor-free after resection of the primary melanoma, and stage III patients after adequate surgical treatment most of the times as well. Only in stage IV there is a metastatic tumor burden with all its consequences.
Impact of high plasma ascorbate levels for cancer development
Ascorbate-rich diets have protective eff ects on cancer development and other age-related diseases [ 14 ] . A recent meta-analysis of 8 case-control studies found a signifi cant preventive eff ect on cervical neoplasms for increased intake of ascorbate [ 15 ] . Further, large epidemiological studies demonstrated a signifi cantly increased risk of dying from cancer for adults [ 13 ] and for men [ 11 ] with low serum ascorbate concentrations. The prospective "European Prospective Investigation into Cancer and Nutrition" study revealed that higher plasma vitamin C levels were associated with a decreased risk of gastric cancer, independent of the particular gastric cancer anatomical subsite or histological subtype [ 12 ] .
Impact of low plasma ascorbate levels for cancer patients
Previous clinical studies demonstrated reduced ascorbate levels in non-melanoma cancer patients [ 4 , 16 ] sometimes even leading to scurvy [ 17 ] . In the latter case series the authors stressed the fact that scurvy should be considered in patients with cancer because of the high incidence of malnutrition caused by chemotherapy, cachexia caused by the disease, and other factors that might lead to an unbalanced dietary intake such as exclusive parenteral nutrition, depression, impaired taste, dysphagia, and abdominal pain. Further, weakness, anorexia, and depression are common in scurvy but also in patients with cancer. The authors concluded that clinicians should suspect ascorbate defi ciency when a patient has haemorrhagic features without a clear explanation [ 17 ] . The importance of ascorbate for innumerable biochemical processes in the human organism is beyond dispute. Since humans and other primates lack the enzyme L-gulonolactone oxidase required for ascorbate synthesis, an adequate oral uptake is vital [ 7 ] . Considering the dependency of the immune system on adequate ascorbate supply [ 8 ] and the importance of the immune system for endogenous tumor control, and that, in addition, stage IV cancer patients frequently suff er from infections caused by therapy-or disease-induced neutrophilia, the additional ascorbate supplementation in physiological doses could be taken into consideration.
Impact of anticancer therapies on plasma ascorbate levels
Our data showed that stage IV melanoma patients are ascorbatedefi cient, and that systemic therapies commonly used on such patients (chemotherapy, immunotherapy) further reduced the plasma ascorbate levels. However, the low number of patients in this cohort (n = 9) limits the generalizability of this fi nding to all stage IV melanoma patients undergoing systemic therapies in spite of its statistical signifi cance. A similar therapeutic phenomenon was described by Marcus and colleagues, who demonstrated a severe ascorbate defi ciency in 11 cancer patients (with metastatic melanoma, hypernephroma, and colon carcinoma), occurring as the result of adoptive immunotherapy with highdose interleukin 2 and lymphokine-activated killer cells [ 8 ] .
Considering that so far no study has shown negative eff ects of ascorbate supplementation in cancer patients, our results suggest that especially late-stage melanoma patients (stage IV) might benefi t from ascorbate supplementation.
Potential anticancer mechanisms of ascorbate on melanoma cells
A number of recent pre-clinical reports have demonstrated a decreased melanoma growth (both after s. c. and intraperitoneal injection) in mice unable to synthesize ascorbic acid (gulonolactone oxidase knockout mice) upon ascorbate supplementation [ 18 , 19 ] . In the latter 2 studies, ascorbate supplementation was accompanied by decreased serum pro-infl ammatory cytokine (IL-6, IL-1β) levels as well as enhanced encapsulation of tumors. IL-6, secreted by melanoma cells, promotes melanoma growth by inhibition of apoptosis and induces tumor angiogenesis. Further, an increased serum concentration of IL-6 correlates with a worse prognosis in melanoma patients [ 20 ] . This obvious impact of ascorbate on the immune response is in line with its crucial role in immunoglobulin synthesis. Moreover, lymphocytes contain high concentrations of ascorbate, and ascorbate is required for phagocytosis and enhances interferon production [ 7 ] . In addition, scorbutic animals show an impairment of lymphocyte activation and macrophage and neutrophil mobilization [ 8 ] .
Together, for the immune response, ascorbate seems to be a double-edged sword functioning both as pro-and anti-infl amma-tory stimulus that inhibits tumor growth. On the cellular level, growth inhibition of melanoma cells was driven by cell cycle arrest and caspase-3 activation with subsequent apoptosis induction [ 21 ] . Further, ascorbate reduced the expression of the transferrin receptor in melanoma cells, resulting in a down-regulation of cellular iron uptake followed by apoptosis induction [ 22 ] . Due to recent pharmacokinetic data showing that intravenous administration of ascorbate results in high plasma levels not achievable by oral uptake and in a signifi cant fl ux of H 2 O 2 to tumors, the use of i. v. ascorbate in pharmacological doses in the treatment of cancer seems plausible and is currently being investigated in clinical trials and in experimental studies [ 23 ] .
Conclusions
▼
We were able to demonstrate that plasma ascorbate levels were signifi cantly lower in stage IV melanoma patients. Systemic therapy on stage IV patients further reduced plasma ascorbate levels. Considering the importance of adequate ascorbate supply for biochemical processes and host defense, our results suggest that late-stage melanoma patients might benefi t from physiological ascorbate supplementation.
